# A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

> **NCT01007292** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 43 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** YM155
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT01007292
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2013-03
- **Final completion:** 2015-06
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2015-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01007292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01007292, "A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01007292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*